secwatch.observer — SEC 8-K summary
======================================

Issuer:     Phathom Pharmaceuticals, Inc. (PHAT)
CIK:        0001783183
Form:       8-K
Filed at:   2023-11-01T23:59:59+00:00
Accession:  0001193125-23-268319
Event type: regulatory
Sentiment:  positive
Materiality: 0.90
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA approves Phathom's VOQUEZNA for Erosive GERD; triggers $175M payment
------------------------------------------------------------------------

- FDA approved VOQUEZNA (vonoprazan) for healing, maintenance, and heartburn relief in Erosive GERD.
- Phase 3 PHALCON-EE trial showed 93% healing rate at Week 8 for VOQUEZNA 20mg vs 85% for lansoprazole.
- VOQUEZNA demonstrated superiority in moderate-to-severe patients (70% vs 53% at Week 2).
- Approval triggers a $175M non-dilutive payment from Revenue Interest Financing Agreement.
- VOQUEZNA expected to launch in US in December 2023; marketed exclusively by Phathom.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1783183/000119312523268319/0001193125-23-268319-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1783183/000119312523268319/d579199d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-268319

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer